Early Prophylactic Use of Curosurf® Versus Newfactan® for Respiratory Distress Syndrome in Premature Infants

Abstract

Purpose: This study was done to compare the prophylactic efficacy of surfactant with Curosurf® and Newfactan®. Methods: Preterm infants treated with pulmonary surfactant within 30 minutes after birth from January 2008 to December 2014 were included in this study. The subjects were divided into a group that received Curosurf® (n=163) and a group that received Newfactan® (n=120). The data were collected retrospectively using the patients' medical records. Results: Demographic factors did not differ between the groups. The incidence rates of surfactant re-dosing, pulmonary air leaks, postnatal steroid therapy use, pulmonary hemorrhage, moderate to severe bronchopulmonary dysplasia, and duration of mechanical ventilation, were not different between the groups. The sequential changes of ventilator parameters after surfactant instillation were not different between the groups. No differences in the incidence rates of patent ductus arteriosus, intraventricular hemorrhage (≥grade III), periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis (≥stage IIa), mortality, sepsis, or duration of hospital stay were observed between the groups. Conclusion: The results indicate no differences in the clinical efficacy of early prophylactic use of Curosurf® versus Newfactan®.